Hemagen Financial Statements From 2010 to 2024
| HMGNDelisted Stock | USD 0.0001 0.00 0.00% |
Check Hemagen Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hemagen main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Hemagen financial statements analysis is a perfect complement when working with Hemagen Diagnostics Valuation or Volatility modules.
Hemagen |
Hemagen Diagnostics Company Operating Margin Analysis
Hemagen Diagnostics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Hemagen Diagnostics Operating Margin | (0.11) % |
Most of Hemagen Diagnostics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemagen Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Hemagen Diagnostics has an Operating Margin of -0.1083%. This is 99.69% lower than that of the Health Care Equipment & Supplies sector and 99.9% lower than that of the Health Care industry. The operating margin for all United States stocks is 98.03% lower than that of the firm.
Hemagen Diagnostics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Hemagen Diagnostics's current stock value. Our valuation model uses many indicators to compare Hemagen Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Hemagen Diagnostics competition to find correlations between indicators driving Hemagen Diagnostics's intrinsic value. More Info.Hemagen Diagnostics is one of the top stocks in return on asset category among related companies. It is one of the top stocks in profit margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Hemagen Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Hemagen Diagnostics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Hemagen Diagnostics' earnings, one of the primary drivers of an investment's value.About Hemagen Diagnostics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Hemagen Diagnostics income statement, its balance sheet, and the statement of cash flows. Hemagen Diagnostics investors use historical funamental indicators, such as Hemagen Diagnostics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Hemagen Diagnostics investors may use each financial statement separately, they are all related. The changes in Hemagen Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Hemagen Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Hemagen Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Hemagen Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company was founded in 1985 and is based in Columbia, Maryland. Hemagen Diagnostics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 15 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Hemagen Diagnostics information on this page should be used as a complementary analysis to other Hemagen Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Hemagen Pink Sheet
If you are still planning to invest in Hemagen Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hemagen Diagnostics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |